Innovation Center for Neurological Disorders, Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
Department of Neurology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, China.
Lancet Neurol. 2020 Jan;19(1):81-92. doi: 10.1016/S1474-4422(19)30290-X. Epub 2019 Sep 4.
China has the largest population of patients with dementia in the world, imposing a heavy burden on the public and health care systems. More than 100 epidemiological studies on dementia have been done in China, but the estimates of the prevalence and incidence remain inconsistent because of the use of different sampling methods. Despite improved access to health services, inadequate diagnosis and management for dementia is still common, particularly in rural areas. The Chinese Government issued a new policy to increase care facilities for citizens older than 65 years, but most patients with dementia still receive care at home. Western medicines for dementia symptoms are widely used in China, but many patients choose Chinese medicines even though they have little evidence supporting efficacy. The number of clinical trials of Chinese and western medicines has substantially increased as a result of progress in research on new antidementia drugs but international multicentre studies are few in number. Efforts are needed to establish a national system of dementia care enhance training in dementia for health professionals, and develop global collaborations to prevent and cure this disease.
中国是世界上痴呆患者人数最多的国家，给公共卫生和医疗系统带来了沉重负担。中国已经开展了 100 多项关于痴呆症的流行病学研究，但由于采用了不同的抽样方法，患病率和发病率的估计仍然不一致。尽管获得医疗服务的机会有所改善，但痴呆症的诊断和管理仍不充分，特别是在农村地区。中国政府出台了一项新政策，增加了为 65 岁以上公民提供的护理设施，但大多数痴呆症患者仍在家中接受护理。西药在治疗痴呆症症状方面得到了广泛应用，但许多患者选择中药，尽管其疗效缺乏证据支持。由于新的抗痴呆药物研究取得了进展，中药和西药的临床试验数量大幅增加，但国际多中心研究的数量却很少。需要努力建立一个全国性的痴呆症护理体系，加强卫生专业人员的痴呆症培训，并开展全球合作，以预防和治疗这种疾病。
